FULC - Fulcrum Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-69.41M

Cash

278.2M

Avg Qtr Burn

-23.12M

Short % of Float

10.40%

Insider Ownership

1.58%

Institutional Own.

98.74%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Losmapimod (p38 inhibitor) Details Muscle degeneration, Muscle weakness	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FTX-6058 (EED inhibitor) Details Sickle cell disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Losmapimod (p38 inhibitor) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.